These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22337897)

  • 1. Pharmacokinetic mismatch of tuberculosis drugs.
    Peloquin CA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1666; author reply 1667. PubMed ID: 22337897
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.
    Srivastava S; Sherman C; Meek C; Leff R; Gumbo T
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5085-9. PubMed ID: 21896907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.
    Zuur MA; Pasipanodya JG; van Soolingen D; van der Werf TS; Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(11):1743-1749. PubMed ID: 29697766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
    Egelund EF; Isaza R; Alsultan A; Peloquin CA
    J Zoo Wildl Med; 2016 Sep; 47(3):868-871. PubMed ID: 27691967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
    Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2004 Apr; 23(4):414-5. PubMed ID: 15081096
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis.
    Barroso EC; Pinheiro VG; Façanha MC; Carvalho MR; Moura ME; Campelo CL; Peloquin CA; Guerrant RL; Lima AA
    Am J Trop Med Hyg; 2009 Aug; 81(2):322-9. PubMed ID: 19635892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy.
    Cappelletty DM
    Int J Antimicrob Agents; 2007 Feb; 29(2):212-6. PubMed ID: 17204402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Genetic Variation of
    Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advantages and disadvantages of longer and shorter chemotherapy regimens for multi-drug or rifampicin-resistant tuberculosis].
    Li Q; Li L
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 May; 42(5):333-338. PubMed ID: 31137109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of Rifampin Resistance in Pulmonary Tuberculosis.
    Kayigire XA; Friedrich SO; van der Merwe L; Diacon AH
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167550
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenges and Outlooks in Multi-drug Resistant Tuberculosis.
    Caminero Luna JA
    Arch Bronconeumol; 2017 Aug; 53(8):417-418. PubMed ID: 28314633
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
    Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.
    Srivastava S; Pasipanodya JG; Meek C; Leff R; Gumbo T
    J Infect Dis; 2011 Dec; 204(12):1951-9. PubMed ID: 22021624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistant tuberculosis: problems on the horizon.
    Ormerod LP
    Thorax; 1993 Oct; 48(10):957-8. PubMed ID: 8256241
    [No Abstract]   [Full Text] [Related]  

  • 15. Rifampin-resistant, isoniazid-susceptible TB in HIV patients.
    Pugliese G
    Infect Control Hosp Epidemiol; 1995 Nov; 16(11):622. PubMed ID: 8601679
    [No Abstract]   [Full Text] [Related]  

  • 16. Mycobacterium tuberculosis in a Saudi Arabian hospital.
    Alrajhi AA
    Chest; 2006 Mar; 129(3):829; author reply 829-30. PubMed ID: 16537892
    [No Abstract]   [Full Text] [Related]  

  • 17. [Molecular diagnosis of Mycobacterium tuberculosis complex resistant to isoniazid and rifampicin in Burkina Faso].
    Désire I; Cyrille B; Florencia D; Souba D; Albert Y; Valerie BJ; Rebecca C; Charlemagne G; Tamboura D; Rémy M; Virginio P; Simplice KD; Martial O; Jacques S
    Pan Afr Med J; 2015; 21():73. PubMed ID: 26491516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterium tuberculosis drug resistance: a call to action.
    Sudre P; Cohn DL
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):609-11. PubMed ID: 9712272
    [No Abstract]   [Full Text] [Related]  

  • 19. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis.
    Cavalieri SJ; Biehle JR; Sanders WE
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1542-5. PubMed ID: 7492101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of rifampicin and isoniazid resistances of Mycobacterium tuberculosis strains by particle counting immunoassay (PACIA).
    Drowart A; Cambiaso CL; Huygen K; Serruys E; Portaels F; Jann E; Van Vooren JP
    Int J Tuberc Lung Dis; 1997 Jun; 1(3):284-8. PubMed ID: 9432378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.